WILMINGTON, Del.--(BUSINESS WIRE)--Extab Corporation, a privately-held, pharmaceutical company focused on advancing Tabex™, a smoking cessation drug containing the active substance cytisine, announces that positive data from a Phase 3 clinical trial of cytisine as a smoking cessation aid were published in the December 18 (Vol 271, No. 25) edition of The New England Journal of Medicine (NEJM) in an article titled, “Cytisine versus Nicotine for Smoking Cessation.” The complete article and a multi
| < Prev | Next > |
|---|
